GeoVax Labs initiates Phase 2 trial of COVID-19 vaccine booster in CLL

GeoVax Labs announced the start of an investigator-initiated clinical trial, titled “Randomized observer-blinded phase 2 trial of COVID-19 booster with GEO-CM04S1 or Pfizer-BioNTech Bivalent vaccine in patients with chronic lymphocytic leukemia, CLL,” at City of Hope National Medical Center, led by Alexey Danilov, M.D., PhD as principal investigator. The primary immune response outcome will be 56 days following the first booster injection. Up to 40 participants will be treated in each arm, with immune responses evaluated at the interim and final analyses in each arm. David Dodd, GeoVax President, and CEO, added, “We are excited to begin this third important study for CM04S1 and look forward to sharing progress reports as we advance. We believe the CM04S1 vaccine, containing the two antigens, S and N, along with the recognized antibody and cellular immune responses resulting from the MVA approach, has the potential to offer greater booster protection than that from the current vaccines in use, as well as provide a greater degree of protection within immunocompromised patients.”